Gerard Bruin

5.9k citations

59 papers · 3.9k indexed · 2 hit papers · h-index 25

Impact in

Immunology top 2%
- Psoriasis: Treatment and Pathogenesis
Dermatology top 1%
- Dermatology and Skin Diseases

Papers in

Immunology 19
- Psoriasis: Treatment and Pathogenesis 13
- Immunodeficiency and Autoimmune Disorders 6
Dermatology 6

Co-authors: Aran Paulus Carlo S. Effenhauser Markus Ehrat H. Poppe J.C. Kraak Wolfgang Hueber Bruce E. Sands Marc Vandemeulebroecke
Journals: Journal of Chromatography A (8 papers)Electrophoresis (5 papers)Drug Metabolism and Disposition (4 papers)Analytical Chemistry (4 papers)Journal of the American Academy of Dermatology (3 papers)
Partner nations: Switzerland United States Netherlands

In The Last Decade

Gerard Bruin

57 papers receiving 3.7k citations

Hit Papers

align trajectories log scale

Secukinumab, a human anti-IL-17A monoclonal antibody, for moderate to severe Crohn's disease: unexpected results of a randomised, double-blind placebo-controlled trial 2012 · 1.2k citations

Peers

Countries citing papers authored by Gerard Bruin

Since Specialization

Citations

This map shows the geographic impact of Gerard Bruin's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Gerard Bruin with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Gerard Bruin more than expected).

Fields of papers citing papers by Gerard Bruin

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Gerard Bruin. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Gerard Bruin. The network helps show where Gerard Bruin may publish in the future.

Co-authors

The 25 scholars most cited alongside Gerard Bruin, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.

Border = papers with Gerard Bruin Line = papers co-authored together Gerard Bruin links everyone, so they are left out of the graph.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work
1	Utility of an in vitro lymphatics on-chip model for rank ordering subcutaneous absorption of monoclonal antibodies Lab on a Chip ·Adriana M. Ledo, Gabriela Misiewicz, Thomas Dimke, William R. Tschantz, J. van den Handel, Ryan M. Pelis, Gerard Bruin, Karoline Bechtold-Peters, Manuel Sánchez-Félix, Sujal V. Deshmukh, Seunggyu Kim, Maria Proestaki, Roger D. Kamm	2025	1
2	An industry perspective on clinical development and regulatory strategies for subcutaneously administered high-dose biologics Journal of Controlled Release ·Gerard Bruin, Ryan P. Nolan, Shelley Amendola, Dany Doucet, Sy Gebrekidan, Tanja Novkovic, Marie Picci, Arpita Raut, Christopher J. Rini, Peter Skutnik, Toms Vengaloor Thomas, Menghui Zhao, Beate Bittner	2025	1
3	Secukinumab in the Treatment of Moderate‐to‐Severe Hidradenitis Suppurativa: Pooled Pharmacokinetics and Safety Results From the SUNSHINE and SUNRISE Phase 3 Studies International Journal of Dermatology ·Afsáneh Alavi, Z. Reguiaï, Gregor B. E. Jemec, Alice B. Gottlieb, Magdalena B. Wozniak, Lorenz Uhlmann, Heng Fan, Angela Llobet Martinez, Gerard Bruin, N. Thomas, Ivette Alarcón, Bruno Bieth, Shoba Ravichandran, Alexa B. Kimball	2025	0
4	Absorption, Distribution, Metabolism, and Excretion of Therapeutic Proteins: Current Industry Practices and Future Perspectives Drug Metabolism and Disposition ·Jayaprakasam Bolleddula, Kevin Brady, Gerard Bruin, Anthony Lee, Jennifer A. Martin, Markus Walles, Keyang Xu, Tong‐Yuan Yang, Xiaochun Zhu, Hongbin Yu	2022	24
5	Characterizing the Pharmacokinetics and Biodistribution of Therapeutic Proteins: An Industry White Paper Drug Metabolism and Disposition ·Kathryn Ball, Gerard Bruin, Enrique Escandón, Christoph Funk, Joao N.S. Pereira, Tong‐Yuan Yang, Hongbin Yu	2022	9
6	Efficacy, tolerability, patient usability, and satisfaction with a 2 mL pre-filled syringe containing secukinumab 300 mg in patients with moderate to severe plaque psoriasis: results from the phase 3 randomized, double-blind, placebo-controlled ALLURE study Journal of Dermatological Treatment ·Bárður Sigurgeirsson, Knut Schäkel, Chih-ho Hong, Isaak Effendy, Waldemar Placek, Phoebe Rich, Deborah Keefe, Gerard Bruin, Pascal Charef, Rong Fu, Isabelle Hampele, Manmath Patekar	2021	13
7	Secukinumab for the treatment of psoriasis, psoriatic arthritis, and axial spondyloarthritis: Physical and pharmacological properties underlie the observed clinical efficacy and safety Pharmacology & Therapeutics ·Frank Kolbinger, Franco Di Padova, Atul Deodhar, Jason E. Hawkes, Christine Huppertz, Torsten Kuiper, Iain B. McInnes, Christopher T. Ritchlin, David Rosmarin, Georg Schett, José M. Carballido, Peter Häusermann, Claudio Calonder, Beate Vogel, Jean‐Michel Rondeau, Gerard Bruin	2021	29
8	β-Defensin 2 is a responsive biomarker of IL-17A–driven skin pathology in patients with psoriasis Journal of Allergy and Clinical Immunology ·Frank Kolbinger, Christian Loesche, Marie‐Anne Valentin, Xiaoyu Jiang, Yi Cheng, Philip Jarvis, Thomas Peters, Claudio Calonder, Gerard Bruin, Florine Polus, Birgit Aigner, David M. Lee, Manfred Bodenlenz, Frank Sinner, Thomas R. Pieber, Dhavalkumar D. Patel	2016	180
9	Secukinumab, a novel anti-IL-17A antibody, exhibits low immunogenicity in clinical trials and human in vitro assays Journal of Dermatological Science ·Frank Kolbinger, Andrew Blauvelt, April W. Armstrong, Todd Fox, Jiaqing Huang, Eric Liang, Annette Karle, Sebastian Spindeldreher, Gerard Bruin, Kristian Reich	2016	1
10	Secukinumab, a human anti-IL-17A monoclonal antibody, for moderate to severe Crohn's disease: unexpected results of a randomised, double-blind placebo-controlled trial Gut ·Wolfgang Hueber, Bruce E. Sands, Steve Lewitzky, Marc Vandemeulebroecke, Walter Reinisch, Peter Higgins, Jan Wehkamp, Brian G. Feagan, Michael Yao, Marek Karczewski, Jacek Karczewski, Nicole Pezous, Stephan Bek, Gerard Bruin, Bjoern Mellgard, C Berger, Marco Londei, Arthur P. Bertolino, Gervais Tougas, Simon Travis, (unknown) Hit paper breakdown →	2012	1156
11	ATF936, a novel oral calcilytic, increases bone mineral density in rats and transiently releases parathyroid hormone in humans Bone ·Markus R. John, Leo Widler, R. Gamse, Thomas Buhl, Klaus Seuwen, Werner Breitenstein, Gerard Bruin, Rossella Belleli, Lloyd B. Klickstein, Michaela Kneissel	2011	32
12	Pharmacokinetics, Metabolism, and Disposition of Deferasirox in β-Thalassemic Patients with Transfusion-Dependent Iron Overload Who Are at Pharmacokinetic Steady State Drug Metabolism and Disposition ·Felix Waldmeier, Gerard Bruin, Ulrike Glaenzel, Katharine Hazell, Romain Séchaud, Steve Warrington, John B. Porter	2010	76
13	Pharmacokinetics, Distribution, Metabolism, and Excretion of Deferasirox and Its Iron Complex in Rats Drug Metabolism and Disposition ·Gerard Bruin, Thomas Faller, Hansjörg Wiegand, Alain Schweitzer, Hanspeter Nick, J. -C. Schneider, K. Olaf Boernsen, Felix Waldmeier	2008	70
14	Immunoaffinity screening with capillary electrochromatography Electrophoresis ·Michael Mayer, Angelika Muscate Magnussen, Horst Vogel, Markus Ehrat, Gerard Bruin	2002	6
15	Fritless capillary electrochromatography Electrophoresis ·Michael Mayer, Erdmann Rapp, Caroline Marck, Gerard Bruin	1999	59
16	Preconcentration and separation of antisense oligonucleotides by on‐column isotachophoresis and capillary electrophoresis in polymer‐filled capillaries Electrophoresis ·Iris Barmé, Gerard Bruin, Aran Paulus, Markus Ehrat	1998	19
17	Integrated chip‐based capillary electrophoresis Electrophoresis ·Carlo S. Effenhauser, Gerard Bruin, Aran Paulus	1997	167
18	Stability measurements of antisense oligonucleotides by capillary gel electrophoresis Journal of Chromatography A ·Gerard Bruin, K. Olaf Börnsen, Dieter Hüsken, Ernst Gassmann, H.M. Widmer, Aran Paulus	1995	22
19	Maternal Antibodies against Equine Influenza Virus in Foals and their Interference with Vaccination Journal of Veterinary Medicine Series B ·J.T. van Oirschot, Gerard Bruin, E. de Boer‐Luytze, G. Smolders	1991	35
20	Performance of carbohydrate-modified fused-silica capillaries for the separation of proteins by zone electrophoresis Journal of Chromatography A ·Gerard Bruin, R.E. Huisden, J.C. Kraak, H. Poppe	1989	109

About Gerard Bruin

Gerard Bruin is a scholar working on Immunology, Dermatology, Spectroscopy, Hematology and Biomedical Engineering, having authored 59 papers that have together received 3.9k indexed citations. Recurring topics across this work include Microfluidic and Capillary Electrophoresis Applications (16 papers), Psoriasis: Treatment and Pathogenesis (13 papers), Innovative Microfluidic and Catalytic Techniques Innovation (9 papers), Analytical Chemistry and Chromatography (8 papers), Microfluidic and Bio-sensing Technologies (8 papers), Monoclonal and Polyclonal Antibodies Research (6 papers), Immunodeficiency and Autoimmune Disorders (6 papers) and Electrowetting and Microfluidic Technologies (5 papers). The work is most often cited by research in Immunology (1.3k citations), Dermatology (355 citations), Biomedical Engineering (1.6k citations), Bioengineering (196 citations) and Hematology (341 citations). Gerard Bruin has collaborated with scholars based in Switzerland, United States and Netherlands. Frequent co-authors include Aran Paulus, Carlo S. Effenhauser, Markus Ehrat, H. Poppe, J.C. Kraak, Wolfgang Hueber, Bruce E. Sands, Marc Vandemeulebroecke, Peter Higgins and Gervais Tougas. Their work appears in journals such as Journal of Chromatography A, Electrophoresis, Drug Metabolism and Disposition, Analytical Chemistry and Journal of the American Academy of Dermatology.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact